BioCentury
ARTICLE | Clinical News

Tefina: Phase II data

August 4, 2014 7:00 AM UTC

The double-blind, international Phase II AMB-2012-01 trial in 253 pre- and post-menopausal women experiencing acquired female orgasmic disorder showed that 0.6 mg Tefina as needed for 84 days met the ...